EPAS1 and nonpapillary renal cell carcinoma: As the above results indicate, ATL-I can inhibit ccRCC proliferation, invasion, and migration and exhibits robust antiangiogenic capacity by inhibiting the EPAS1-VEGFA signaling pathway.